雷米普利在急性心肌梗死合并心力衰竭患者中的长期生存获益
基于AIRE研究英国队列603例急性心肌梗死合并临床心力衰竭患者,随机接受雷米普利或安慰剂,平均掩蔽治疗约12–13个月,随访至29.6年。雷米普利组较安慰剂组延长寿命14.5个月(95%CI 13.2–15.8),合并糖尿病、既往心梗、既往心衰、高血压、心绞痛及年龄>65岁者获益更大。
要点
- 急性心梗合并临床心衰患者,雷米普利平均约13个月治疗带来持续生存获益
- 平均寿命延长14.5个月(95%CI 13.2–15.8)
- 糖尿病、既往心梗或心衰、高血压、心绞痛及高龄患者绝对获益更明显
核心结论
- 对急性心肌梗死合并临床心力衰竭患者,雷米普利带来持续生存获益,平均约13个月治疗使寿命延长达14.5个月。
研究设计与样本
- 1993年AIRE研究随机分配急性心肌梗死合并临床心力衰竭患者接受雷米普利或安慰剂。
- 英国队列603例,平均年龄64.7岁,男性455例;雷米普利组302例、安慰剂组301例。
- 掩蔽治疗时间雷米普利组12.4个月、安慰剂组13.4个月,随访范围0–29.6年,估算预期寿命与寿命延长。
主要发现
- 截至2019年4月9日,安慰剂组全因死亡266例(88.4%),雷米普利组275例(91.1%)。
- 雷米普利组较安慰剂组寿命延长14.5个月(95%CI 13.2–15.8)。
- 糖尿病者寿命延长32.1个月 vs 无糖尿病者5.0个月,既往心梗20.1 vs 4.9个月,既往心衰19.5 vs 4.9个月。
- 高血压16.6 vs 8.3个月,心绞痛16.2 vs 5.0个月,年龄>65岁11.3 vs 5.7个月。
- 考虑潜在治疗转换后,真实绝对治疗效应可能被低估28%。
关键数值与推荐
- 寿命延长定义为中位生存时间差值,雷米普利较安慰剂为14.5个月(95%CI 13.2–15.8)。
- 亚组寿命延长:糖尿病32.1个月、既往心梗20.1个月、既往心衰19.5个月、高血压16.6个月、心绞痛16.2个月、年龄>65岁11.3个月。
临床怎么用
- 对急性心肌梗死合并临床心力衰竭患者,应考虑使用雷米普利以获取长期生存获益。
- 合并糖尿病、既往心梗、既往心衰、高血压、心绞痛或高龄者绝对获益可能更大,可优先强化ACE抑制剂治疗。
局限性
- 为英国队列的事后长期随访分析,非原随机对照试验的长期设计。
- 存在潜在治疗转换,真实绝对治疗效应可能被低估28%。
- 原文未报告长期随访期间的具体用药调整与停药比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: ACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population. METHODS: In 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0-29.6 years). RESULTS: By 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%. CONCLUSION: For patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.
引用
- Wu J, Hall AS, Gale CP, et al. Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure. Heart. 2021. PMID: 33452123. doi:10.1136/heartjnl-2020-316823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。